Lisa A. Carey, MD, on the CALGB/Alliance 40603 Trial

2014 San Antonio Breast Cancer Symposium

Lisa A. Carey, MD, of the UNC Lineberger Comprehensive Cancer Center, addresses further analysis of data from abstract S4-05, “Impact of intrinsic subtype by PAM50 and other gene signatures on pathologic complete response rates in triple-negative breast cancer after neoadjuvant chemotherapy with or without carboplatin or bevacizumab: CALGB 40603/150709,” presented by William M. Sikov, MD.

Prudence Francis, MD, and Hope Rugo, MD, on the Phase III SOFT Trial

Prudence Francis, MD, of Peter MacCallum Cancer Centre, and Hope Rugo, MD, of the University of California, San Francisco, discuss data from abstract S3-08,

Breast Cancer

Harold J Burstein MD PhD and Lisa A Carey MD

Harold J. Burstein, MD, PhD, and Lisa A. Carey, MD, on Innovations in Triple-Negative Breast Cancer

Harold J. Burstein, MD, PhD, of the Dana-Farber Cancer Institute and Lisa Carey, MD, of the UNC Lineberger Comprehensive Cancer Center, discuss:

Breast Cancer

Charles E. Geyer, Jr, MD, FACP

Charles E. Geyer, Jr, MD, FACP, on the NSABP B-36 Trial

Charles E. Geyer, Jr, MD, FACP, of Massey Cancer Center, discusses findings from abstract S3-02,

Breast Cancer

Matthew J. Ellis, MD, PhD, and Harold J. Burstein, MD, PhD

Matthew J. Ellis, MD, PhD, and Harold J. Burstein, MD, PhD, on Genome-Directed Therapeutics for Endocrine Therapy-Resistant ER-Positive Breast Cancer

Matthew J. Ellis, MD, PhD, of the Baylor College of Medicine discusses with Harold J. Burstein, MD, PhD, of the Dana-Farber Cancer Institute genome-directed therap...

Breast Cancer

Lisa A. Carey, MD

Lisa A. Carey, MD, on the TNT Trial

Lisa A. Carey, MD, of the UNC Lineberger Comprehensive Cancer Center, discusses abstract S3-01,

May

Today In Oncology

Harold J. Burstein, MD, PhD, and Lisa A. Carey, MD, on Innovations in Triple-Negative Breast Cancer

Charles E. Geyer, Jr, MD, FACP, on the NSABP B-36 Trial

Matthew J. Ellis, MD, PhD, and Harold J. Burstein, MD, PhD, on Genome-Directed Therapeutics for Endocrine Therapy-Resistant ER-Positive Breast Cancer

Phase II Study of Trilaciclib in Pretreated Patients With Metastatic NSCLC Initiated PRESERVE 4

Safety of Stereotactic Body Radiotherapy for Treatment of Patients With Multiple Metastases

FDA ODAC Votes in Favor of Retaining Accelerated Approval for Bladder Cancer Treatments

Expert Panel–Endorsed Quality Measures for End-of-Life Care for Children With Cancer

One vs Two Doses of the BNT162b2 COVID-19 Vaccine in Patients With Cancer: Immunogenicity and Efficacy

Lisa A. Carey, MD, on the CALGB/Alliance 40603 Trial

Related Videos

Prudence Francis, MD, and Hope Rugo, MD, on the Phase III SOFT Trial

Lisa A. Carey, MD, on the TNT Trial